Citations

Showing 10 of 108104 citations.

Prevention of Clostridium difficile Infection in Critically Ill Adults
Leedahl, David D. , Personett, Heather A. , Nagpal, Avish , Frazee, Erin N. , Frazee, Erin N

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | December 3, 2018 | Volume: 39 | Issue: 3 | Pages: 399-407

10.1002/phar.2200 | PMID 30506900 Get It

The incidence and severity of Clostridium difficile infection (CDI) remain high across intensive care units in the United States despite national efforts to decrease this escalating health care burden. Most published literature and guidelines address treatment rather than prevention, yet this approach may be too downstream to limit morbidity and mortality from the disease and its complications. Mechanisms to prevent CDI successfully include reducing modifiable risk factors and minimizing horizontal transmission of C. difficile spores between patients and the health care environment. Because CDI prevention is characterized by a bundled approach, it is difficult to quantify the individual impact of any one element; however, a number of patient‐ and facility‐level strategies can be considered for CDI prevention. Robust hygiene strategies, diagnostic and antimicrobial stewardship, and particular prophylaxis maneuvers such as continuation of oral vancomycin or fidaxomicin in the setting of systemic antibiotics have all demonstrated benefit. The preventive roles of deprescribing acid suppressants, routine use of probiotics, or early fecal microbiota transplantation remain unclear. The focus of this review is to summarize the evidence related to primary and secondary CDI prevention in critically ill adults and provide a concise implementation pathway for clinicians and policymakers.
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis
Brown, Jennifer R. , Moslehi, Javid J. , Ewer, Michael S. , O’Brien, Susan , Ghia, Paolo , Cymbalista, Florence, Shanafelt, Tait D. , Fraser, Graeme , Rule, Simon , Dilhuydy, Marie‐Sarah, Cramer, Paula , Jaeger, Ulrich, Dreyling, Martin , Byrd, John C., Liu, Emily Y., Chang, Stephen, Bista, Amulya, Vempati, Rama, Boornazian, Lisa, Valentino, Rudolph, Reddy, Vijay , Mahler, Michelle, Yang, Huiying , Graef, Thorsten , Byrd, John C. , Treon, Steven , Burger, Jan A , Shanafelt, Tait D , Ghia, Paolo , Coutré, Steven , Dilhuydy, Marie‐Sarah, Byrd, John C. , Treon, Steven P. , Bista, Amulya R, Burger, Jan A. , Byrd, John C

Mayo Clinic

British Journal of Haematology | December 3, 2018 | Volume: 184 | Issue: 4 | Pages: 558-569

10.1111/bjh.15690 | PMID 30506764 Get It

SummaryIbrutinib, a Bruton tyrosine kinase inhibitor, is approved for treatment of various B‐cell malignancies. In ibrutinib clinical studies, low‐grade haemorrhage was common, whereas major haemorrhage (MH) was infrequent. We analysed the incidence of and risk factors for MH from 15 ibrutinib clinical studies (N = 1768), including 4 randomised controlled trials (RCTs). Rates of any‐grade bleeding were similar for single‐agent ibrutinib and ibrutinib combinations (39% and 40%). Low‐grade bleeding was more common in ibrutinib‐treated than comparator‐treated patients (35% and 15%), and early low‐grade bleeding was not associated with MH. The proportion of MH in RCTs was higher with ibrutinib than comparators (4.4% vs. 2.8%), but after adjusting for longer exposure with ibrutinib (median 13 months vs. 6 months), the incidence of MH was similar (3.2 vs. 3.1 per 1000 person‐months). MH led to treatment discontinuation in 1% of all ibrutinib‐treated patients. Use of anticoagulants and/or antiplatelets (AC/AP) during the study was common (~50% of patients) and had an increased exposure‐adjusted relative risk for MH in both the total ibrutinib‐treated population (1.9; 95% confidence interval, 1.2–3.0) and RCT comparator‐treated patients (2.4; 95% confidence interval, 1.0–5.6), indicating that ibrutinib may not alter the effect of AC/AP on the risk of MH in B‐cell malignancies.
Neurocognitive Difficulties Among Youth with POTS within an Intensive Pain Rehabilitation Program
Owens, Michele Tsai , Harbeck‐Weber, Cynthia , Kirsch, Alexandra C. , Sim, Leslie , Zaccariello, Michael J. , Homan, Kendra J. , Kirsch, Alexandra, Zaccariello, Michael, Fischer, Philip , Harbeck‐Weber, Cynthia , Fischer, Philip R.

Mayo Clinic

Journal of Pediatric Psychology | December 3, 2018 | Volume: 44 | Issue: 5 | Pages: 567-575

10.1093/jpepsy/jsy106 | PMID 30649432 Get It

Biopharmaceutical Drug Development Pillars: Begin With the End in Mind
Welch, Anthony , Salomon, Rachelle, Boroumand, Soulmaz, Welch, Anthony R.

Mayo Clinic

Clinical Pharmacology & Therapeutics | December 3, 2018 | Volume: 105 | Issue: 1 | Pages: 33-35

10.1002/cpt.1273 | PMID 30506670 Get It

A Trans-Atlantic Perspective on Stagnation in Clinical Translation of Antimicrobial Strategies for the Control of Biomaterial-Implant-Associated Infection
Busscher, Henk J. , Mei, Henny C. van der , Fagette, Paul, Zimmerli, Werner, Schmidmaier, Gerhard , Raschke, Michael J. , Gehrke, Thorsten , Bayston, Roger , Winterton, Lynn, Darouiche, Rabih O., Grainger, David W. , Alt, Volker , Moriarty, T Fintan , Parvizi, Javad , Gehrke, Thorsten A. , Baddour, Larry M.

Mayo Clinic

ACS Biomaterials Science & Engineering | December 2, 2018 | Volume: 5 | Issue: 2 | Pages: 402-406

10.1021/acsbiomaterials.8b01071 | PMID 30775431 Get It

Bivalirudin versus heparin in patients undergoing percutaneous peripheral interventions: A systematic review and meta-analysis
Olmedo, Wilman, Villablanca, Pedro , Sanina, Cristina , Weinreich, Michael , Brevik, Jeannine, Avendaño, Ricardo , Bravo, Claudio , Babaev, Anvar, Attubato, Michael , Hernandez-Suarez, DF, Cox‐Alomar, Pedro, Pyo, Robert, Krishnan, Prakash , Wiley, José , Villablanca, Pedro A , Avendano, Ricardo , Ramakrishna, Harish , Hernandez-Suarez, D F , Walker, Jonathan R. , Romero, Jorge E.

Mayo Clinic

Vascular | December 1, 2018 | Volume: 27 | Issue: 1 | Pages: 78-89

10.1177/1708538118807522 | PMID 30501582 Get It

Background Bivalirudin may be an effective alternative anticoagulant to heparin for use in percutaneous peripheral interventions. We aimed to compare the safety and efficacy of bivalirudin versus heparin as the procedural anticoagulant agent in patients undergoing percutaneous peripheral intervention. Methods For this meta-analysis and systematic review, we conducted a search in PubMed, Medline, Embase, and Cochrane for all the clinical studies in which bivalirudin was compared to heparin as the procedural anticoagulant in percutaneous peripheral interventions. Outcomes studied included all-cause mortality, all-bleeding, major and minor bleeding, and access site complications. Results Eleven studies were included in the analysis, totaling 20,137 patients. There was a significant difference favoring bivalirudin over heparin for all-cause mortality (risk ratio 0.58, 95% CI 0.39–0.87), all-bleeding (risk ratio 0.62, 95% CI 0.50–0.78), major bleeding (risk ratio 0.61, 95% CI 0.39–0.96), minor bleeding (risk ratio 0.66, 95% CI 0.47–0.92), and access site complications (risk ratio 0.66, 95% CI 0.51–0.84). There was no significant difference in peri-procedural need for blood transfusions (risk ratio 0.79, 95% CI 0.57–1.08), myocardial infarction (risk ratio 0.87, 95% CI 0.59–1.28), stroke (risk ratio 0.77, 95% CI 0.59–1.01), intracranial bleeding (risk ratio 0.77, 95% CI 0.29–2.02), or amputations (OR 0.75, 95% CI 0.53–1.05). Conclusion Our meta-analysis suggests that bivalirudin use for percutaneous peripheral interventions is associated with lower all-cause mortality, bleeding, and access site complications as compared to heparin. Further large randomized trials are needed to confirm the current results.
Leveraging the Electronic Health Record to Create an Automated Real‐Time Prognostic Tool for Peripheral Arterial Disease
Arruda‐Olson, Adelaide M. , Afzal, Naveed , Mallipeddi, Vishnu Priya , Said, Ahmad , Pacha, Homam Moussa , Chaudhry, Alisha P., Bailey, Kent R. , Rooke, Thom W. , Wennberg, Paul W. , Kaggal, Vinod C. , Oderich, Gustavo S. , Chaudhry, Rajeev , Priya Mallipeddi, Vishnu, Moussa Pacha, Homam, Afzal, Naveed, Moon, Sungrim , Chaudhry, Alisha P., Scott, Christopher G. , Oderich, Gustavo S. , Kullo, Iftikhar J. , Nishimura, Rick A. , Liu, Hongfang

Mayo Clinic

Journal of the American Heart Association | December 1, 2018 | Volume: 7 | Issue: 23 | Pages: No page available

10.1161/jaha.118.009680 | PMID 30571601 Get It

Background Automated individualized risk prediction tools linked to electronic health records ( EHR s) are not available for management of patients with peripheral arterial disease. The goal of this study was to create a prognostic tool for patients with peripheral arterial disease using data elements automatically extracted from an EHR to enable real‐time and individualized risk prediction at the point of care. Methods and Results A previously validated phenotyping algorithm was deployed to an EHR linked to the Rochester Epidemiology Project to identify peripheral arterial disease cases from Olmsted County, MN, for the years 1998 to 2011. The study cohort was composed of 1676 patients: 593 patients died over 5‐year follow‐up. The c‐statistic for survival in the overall data set was 0.76 (95% confidence interval [CI], 0.74–0.78), and the c‐statistic across 10 cross‐validation data sets was 0.75 (95% CI, 0.73–0.77). Stratification of cases demonstrated increasing mortality risk by subgroup (low: hazard ratio, 0.35 [95% CI, 0.21–0.58]; intermediate‐high: hazard ratio, 2.98 [95% CI, 2.37–3.74]; high: hazard ratio, 8.44 [95% CI, 6.66–10.70], all P <0.0001 versus the reference subgroup). An equation for risk calculation was derived from Cox model parameters and β estimates. Big data infrastructure enabled deployment of the real‐time risk calculator to the point of care via the EHR . Conclusions This study demonstrates that electronic tools can be deployed to EHR s to create automated real‐time risk calculators to predict survival of patients with peripheral arterial disease. Moreover, the prognostic model developed may be translated to patient care as an automated and individualized real‐time risk calculator deployed at the point of care.
Acute Post-Inflatable Penile Prosthesis Glans Ischemia: Review of Incidence, Pathophysiology, and Management Recommendations
Hebert, Kevin , Kohler, T, Hebert, Kevin J

Mayo Clinic

The Journal of Sexual Medicine | December 1, 2018 | Volume: 16 | Issue: 1 | Pages: 1-4

10.1016/j.jsxm.2018.10.017 | PMID 30509507 Get It

Longitudinal Occurrence and Predictors of Patient‐Provider Discordance Between Global Assessments of Disease Activity in Rheumatoid Arthritis: A Case–Control Study
Challa, Divya N. V., Kvrgic, Zoran, Crowson, Cynthia S. , Matteson, Eric L. , Mason, Thomas G. , Michet, Clement J. , Wright, Kerry , Davis, John M. , Schaffer, Daniel E, Wright, Kerry A, Davis, John M , Mason, Thomas G., Schäffer, Daniel E.

Mayo Clinic

Arthritis Care & Research | November 30, 2018 | Volume: 72 | Issue: 1 | Pages: 18-26

10.1002/acr.23819 | PMID 30506552 Get It

ObjectiveTo identify longitudinal predictors of discordance between patients with rheumatoid arthritis (RA) and their health care providers, where patient global assessment of disease activity is substantially higher than provider global assessment.MethodsThis retrospective case–control study included 102 cases with positive discordance (i.e., ≥25 mm between patient and provider global assessments) and 102 controls without discordance who were matched for age, sex, RA duration, and Clinical Disease Activity Index (CDAI) score. Data were collected at the baseline visit (date of diagnosis or earliest available visit), the index visit (participation in a previous cross‐sectional study), and at up to 11 additional visits before the index visit. Data included patient characteristics, disease activity measures, Disease Activity Score in 28 joints (3‐variable) using the C‐reactive protein level (DAS28‐CRP), and medications. Data were analyzed by using linear and logistic regression models with smoothing splines for nonlinear trends.ResultsOverall, the mean age was 63 years, 75% of patients were female, and the mean RA duration was 10 years. Compared with controls, cases had higher rates of discordant visits during the 4 years before the index visit, and they had a higher CDAI score and DAS28‐CRP earlier in the disease course. Cases more frequently had antinuclear antibodies, nonerosive disease, prior depression, or prior use of antidepressants or fibromyalgia medications. Disease‐modifying medication use was not different between cases and controls.ConclusionThe findings inform new hypotheses about the relationships of disease activity and antinuclear antibodies to the later occurrence of positive discordance among patients with RA.